HR1532Referred to Committee

Scientific EXPERT Act of 2025

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-02-24
Introduced
6
Cosponsors
HR
ⓘ
Type

Sponsor

Doris O. Matsui
Doris O. Matsui
Democrat · CA · Representative
Votes with party: 97.8% (672 recorded votes)

Full profile: /officials/M001163

Source: Congress.gov · FEC

Cosponsors (6)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

6 cosponsors on record at Congress.gov. The named list is syncing into Govwatch and will appear here shortly — view on Congress.gov in the meantime.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the House Committee on Energy and Commerce.

2025-02-24

Source: Congress.gov

Committee Activity

Currently in

Plain-English Summary

Scientific External Process for Educated Review of Therapeutics Act of 2025 or the Scientific EXPERT Act of 2025 This bill requires the Food and Drug Administration (FDA) to facilitate and participate in externally led, science-focused drug development meetings to discuss the development of treatments for rare diseases and conditions. The FDA must enter into an arrangement with the Reagan-Udall Foundation for the FDA under which the foundation agrees to convene such meetings. Meetings must be held at least four times a year, and each meeting must focus on a different rare disease or condition. The foundation must establish a permanent steering committee to review and recommend topics for each meeting. In evaluating potential topics, the committee must consider unmet therapeutic needs, patient population sizes for different diseases and conditions, and whether a disease or condition would benefit from clarity and alignment on drug development questions, among other factors. In planning each meeting, the foundation must develop a list of medical experts, drug sponsors, scientific organizations, patient organizations, and other entities to be invited to participate. Representatives of the FDA’s review divisions must attend each meeting. After each meeting, the foundation must make available a summary of the meeting noting areas of consensus, areas where additional clarification or information is needed, and next steps agreed upon with the FDA. The bill also requires the FDA to indicate whether it incorporated any input from these meetings when approving a new drug or biologic.

Plain-English rewrite of the Congressional Research Service summary published on Congress.gov. Cached and reviewed.

Subjects

Health
Full bill text is not yet cached locally.

Related legislation

Bills by the same sponsor or covering overlapping subjects.